Literature DB >> 19967931

Sir Arnold Theiler and the discovery of anaplasmosis: a centennial perspective.

G H Palmer1.   

Abstract

Sir Arnold Theiler's research in 1908/09 led to the discovery of the first rickettsial pathogen, Anaplasma marginale, and set the stage for his development and implementation of an effective live vaccine based on a less virulent strain, A. marginale ss. centrale. His 1910 report, describing A. marginale, is among the classic monographs in infectious disease research, presenting not only observations in exacting detail but also highlighting the deductive reasoning leading to association of a new pathogen with a specific disease. With a centennial perspective and both conceptual frameworks and molecular tools unimaginable in Theiler's time, the significance of several observations in the original report--cyclic bacteremia, strain superinfection, and taxonomic position--is now clear and highlight the broad applicability of key principles of pathogen biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19967931     DOI: 10.4102/ojvr.v76i1.68

Source DB:  PubMed          Journal:  Onderstepoort J Vet Res        ISSN: 0030-2465            Impact factor:   1.792


  3 in total

1.  Identification of Anaplasma marginale outer membrane protein antigens conserved between A. marginale sensu stricto strains and the live A. marginale subsp. centrale vaccine.

Authors:  Joseph T Agnes; Kelly A Brayton; Megan LaFollett; Junzo Norimine; Wendy C Brown; Guy H Palmer
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

2.  Antigenic Variation in Bacterial Pathogens.

Authors:  Guy H Palmer; Troy Bankhead; H Steven Seifert
Journal:  Microbiol Spectr       Date:  2016-02

3.  Anaplasma marginale superinfection attributable to pathogen strains with distinct genomic backgrounds.

Authors:  Eduardo Vallejo Esquerra; David R Herndon; Francisco Alpirez Mendoza; Juan Mosqueda; Guy H Palmer
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.